Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Lifecore Biomedical, Inc. - Common Stock (NQ: LFCR ) 4.950 -0.080 (-1.59%) Streaming Delayed Price Updated: 12:27 PM EDT, Jul 10, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Lifecore Biomedical, Inc. - Common Stock < Previous 1 2 Next > The Law Offices of Frank R. Cruz Announces Investigation of Lifecore Biomedical, Inc. (LFCR) on Behalf of Investors March 26, 2024 From Law Offices of Frank R. Cruz Via Business Wire Lifecore Biomedical Announces Pending Change of Auditor and Provides Expectation for Business Update March 26, 2024 From Lifecore Biomedical, Inc. Via GlobeNewswire Lifecore Class Action Lawsuit Investigation News – Potential to Make Claim, Recover Losses, Contact Johnson Fistel, LLP March 24, 2024 From Johnson Fistel, LLP Via Business Wire LIFECORE ALERT: Bragar Eagel & Squire, P.C. is Investigating Lifecore Biomedical, Inc. on Behalf of Lifecore Stockholders and Encourages Investors to Contact the Firm March 22, 2024 From Bragar Eagel & Squire Via GlobeNewswire Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Lifecore Biomedical, Inc. (LFCR) March 21, 2024 From Kirby McInerney LLP Via Business Wire Lifecore Biomedical Concludes Strategic Evaluation Process, Announces Management Succession and Board Changes March 20, 2024 From Lifecore Biomedical, Inc. Via GlobeNewswire Lifecore Biomedical Completes Restatements and Files Form 10-K for Fiscal Year 2023 March 20, 2024 Efforts now aligned toward the completion of its First Quarter Fiscal 2024 Report on Form 10-Q From Lifecore Biomedical, Inc. Via GlobeNewswire Lifecore Biomedical, Inc. Announces Receipt of Nasdaq Notice of Delisting and Intention to Appeal February 16, 2024 Notice of Delisting Will Not Immediately Result in the Suspension or Delisting of the Company’s Securities From Lifecore Biomedical, Inc. Via GlobeNewswire Lifecore Biomedical, Inc. Receives Notice from Nasdaq Regarding Delayed Quarterly Report January 12, 2024 From Lifecore Biomedical, Inc. Via GlobeNewswire Lifecore Biomedical Expands Relationship with Existing Long-Term Customer Through a Series of Commercial Arrangements January 05, 2024 From Lifecore Biomedical, Inc. Via GlobeNewswire Lifecore Biomedical Provides Business Update December 13, 2023 From Lifecore Biomedical, Inc. Via GlobeNewswire Company Reaches Favorable Resolution Regarding Previously-Disclosed Investigation of Formerly-Held Subsidiary Yucatan Foods November 20, 2023 U.S. Department of Justice Declines Prosecution From Lifecore Biomedical, Inc. Via GlobeNewswire Lifecore Biomedical, Inc. Receives Notice from Nasdaq Regarding Delayed Annual Report October 18, 2023 From Lifecore Biomedical, Inc. Via GlobeNewswire Lifecore Biomedical Provides Update for Development Portfolio and Timing of Delayed Filings October 10, 2023 From Lifecore Biomedical, Inc. Via GlobeNewswire Lifecore Biomedical Reports Fourth Quarter and Full Fiscal Year 2023 Results August 31, 2023 From Lifecore Biomedical, Inc. Via GlobeNewswire Lifecore Biomedical Sets Fourth Quarter 2023 Earnings Conference Call for August 31, 2023 at 7:30 a.m. CT August 22, 2023 From Lifecore Biomedical, Inc. Via GlobeNewswire Lifecore Biomedical, Inc. Receives Notice from Nasdaq Regarding Delayed Annual Report August 22, 2023 From Lifecore Biomedical, Inc. Via GlobeNewswire Lifecore Biomedical Reports Third Quarter Fiscal Year 2023 Results June 01, 2023 Going concern qualification is removed as a result of the $150 million new financing transaction announced last week From Lifecore Biomedical, Inc. Via GlobeNewswire Lifecore Biomedical Enters into $150.0 Million in New Financing, Repays its Outstanding Term Loans and Signs New Supply Agreement to Expand HA Fermentation Capacity with Existing Long-Term Customer May 22, 2023 New $150 million credit arrangements include six-year credit agreement and equipment sale and leaseback to replace existing term loan From Lifecore Biomedical, Inc. Via GlobeNewswire Lifecore Biomedical Sets Third Quarter 2023 Earnings Conference Call for June 1, 2023 at 7:30 a.m. CT May 22, 2023 From Lifecore Biomedical, Inc. Via GlobeNewswire Lifecore Biomedical, Inc. Receives Notice from Nasdaq Regarding Delayed Quarterly Report April 14, 2023 From Lifecore Biomedical, Inc. Via GlobeNewswire Lifecore Biomedical Announces Sale of Curation Foods’ O Olive Oil and Vinegar® Business April 06, 2023 From Lifecore Biomedical, Inc. Via GlobeNewswire Lifecore Biomedical Signs Term Sheet with Existing Long-Term Customer to Expand CDMO Relationship March 16, 2023 From Lifecore Biomedical, Inc. Via GlobeNewswire Lifecore Biomedical Announces Intent to Explore Strategic Alternatives March 16, 2023 From Lifecore Biomedical, Inc. Via GlobeNewswire Lifecore Biomedical Reports Second Quarter Fiscal Year 2023 Results March 16, 2023 From Lifecore Biomedical, Inc. Via GlobeNewswire Lifecore Biomedical Announces Sale of Curation Foods’ Avocado Products Business February 07, 2023 Proceeds to be used for debt paydown From Lifecore Biomedical, Inc. Via GlobeNewswire Lifecore Biomedical Receives Notice from Nasdaq Regarding Delayed Quarterly Report January 11, 2023 From Lifecore Biomedical, Inc. Via GlobeNewswire Lifecore Biomedical Raises Capital with Private Placement of Convertible Preferred Stock; Amends Credit Facilities January 09, 2023 From Lifecore Biomedical, Inc. Via GlobeNewswire Lifecore Biomedical Raises Capital for Growth with Existing Stockholder November 25, 2022 $5 million PIPE supports near-term capital needs to meet equipment milestones From Lifecore Biomedical, Inc. Via GlobeNewswire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
